Please assess the completion status of the following clinical trial:

Trial Title: Olmesartan Pediatric Pharmacokinetic (PK) Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 12 months to 16 years inclusive~* Signed parental/guardian informed consent and assent from the subject~* Current treatment for hypertension, or, if not currently treated for hypertension, systolic blood pressure (SBP) greater than or equal to 95th percentile for gender and height-for-age, or, if not currently treated for hypertension, systolic blood pressure or diastolic blood pressure greater than or equal to 90th percentile for gender and height-for-age and diabetic or having a family history of hypertension~* Glomerular filtration rate (GFR) greater than or equal to 30 mL/min/1.73 m2, estimated using the Schwartz equation~* Sexually active females of child-bearing potential must be practicing an acceptable method of birth control~* Negative serum beta-human chorionic gonadotropin at screening and at admission (female of child-bearing potential only)~Exclusion Criteria:~* Clinically significant cardiac, gastrointestinal, hematologic, hepatic or hepatobiliary, neurologic, or pulmonary (except asthma) disorder~* History of severe or symptomatic hypertension associated with stroke, seizures, encephalopathy, or other significant neurologic findings within 1 year prior to screening~* Current treatment with more than 2 antihypertensive medications~* Secondary hypertension from uncorrected coarctation of the aorta, bilateral renal artery stenosis, or unilateral renal artery stenosis in a single kidney~* Serum albumin \< 2.5 g/dL~* Major organ or bone marrow transplantation except for prior kidney transplantation of at least 6 months and with stable renal function meeting the inclusion criteria

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Olmesartan (Type: EXPERIMENTAL): Children less than 6 years old received 0.3 mg/kg. Children 6 years old or older received 40 mg, if they weighed 35 kg or more; 20 mg if they weighed less than 35 kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).